A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
This study is a Phase 2 multicenter, randomized, placebo controlled, single-blind study. The
primary objective of the study is to compare the effect of weekly dosing of LJPC-401
(synthetic human hepcidin) versus placebo on transferrin saturation (TSAT) in an adult
hereditary hemochromatosis patient population.